SVRA Quote, Financials, Valuation and Earnings

NovaBay Pharmaceuticals, Inc. has a net margin of -- compared to Savara, Inc.'s net margin of -255.85%. Savara, Inc.'s return on equity of -78.83% beat NovaBay Pharmaceuticals, Inc.'s return on equity of -306.03%.

Savara, Inc. has a consensus price target of $10.81, signalling upside risk potential of 92.74%. On the other hand NovaBay Pharmaceuticals, Inc. has an analysts' consensus of $0.85 which suggests that it could fall by -57.5%. Given that Savara, Inc. has higher upside potential than NovaBay Pharmaceuticals, Inc., analysts believe Savara, Inc. is more attractive than NovaBay Pharmaceuticals, Inc..

Savara, Inc. has a beta of 0.278, which suggesting that the stock is 72.168% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals, Inc. has a beta of 0.093, suggesting its less volatile than the S&P 500 by 90.725%.

Savara, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.80 per share. Savara, Inc. pays -- of its earnings as a dividend. NovaBay Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Savara, Inc. quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals, Inc. quarterly revenues of $521K. Savara, Inc.'s net income of -$29.6M is lower than NovaBay Pharmaceuticals, Inc.'s net income of -$1.3M. Notably, Savara, Inc.'s price-to-earnings ratio is -- while NovaBay Pharmaceuticals, Inc.'s PE ratio is 3.36x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Savara, Inc. is -- versus 3.89x for NovaBay Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Palatin Technologies has a net margin of -- compared to Savara, Inc.'s net margin of --. Savara, Inc.'s return on equity of -78.83% beat Palatin Technologies's return on equity of --.

Savara, Inc. has a consensus price target of $10.81, signalling upside risk potential of 92.74%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 7338.9%. Given that Palatin Technologies has higher upside potential than Savara, Inc., analysts believe Palatin Technologies is more attractive than Savara, Inc..

Savara, Inc. has a beta of 0.278, which suggesting that the stock is 72.168% less volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.939, suggesting its less volatile than the S&P 500 by 6.103%.

Savara, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Savara, Inc. pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.

Savara, Inc. quarterly revenues are --, which are larger than Palatin Technologies quarterly revenues of --. Savara, Inc.'s net income of -$29.6M is higher than Palatin Technologies's net income of --. Notably, Savara, Inc.'s price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Savara, Inc. is -- versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.

Sensus Healthcare, Inc. has a net margin of -- compared to Savara, Inc.'s net margin of -13.7%. Savara, Inc.'s return on equity of -78.83% beat Sensus Healthcare, Inc.'s return on equity of -5.65%.

Savara, Inc. has a consensus price target of $10.81, signalling upside risk potential of 92.74%. On the other hand Sensus Healthcare, Inc. has an analysts' consensus of $7.33 which suggests that it could grow by 43.51%. Given that Savara, Inc. has higher upside potential than Sensus Healthcare, Inc., analysts believe Savara, Inc. is more attractive than Sensus Healthcare, Inc..

Savara, Inc. has a beta of 0.278, which suggesting that the stock is 72.168% less volatile than S&P 500. In comparison Sensus Healthcare, Inc. has a beta of 1.211, suggesting its more volatile than the S&P 500 by 21.098%.

Savara, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sensus Healthcare, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Savara, Inc. pays -- of its earnings as a dividend. Sensus Healthcare, Inc. pays out -- of its earnings as a dividend.

Savara, Inc. quarterly revenues are --, which are smaller than Sensus Healthcare, Inc. quarterly revenues of $6.9M. Savara, Inc.'s net income of -$29.6M is lower than Sensus Healthcare, Inc.'s net income of -$943K. Notably, Savara, Inc.'s price-to-earnings ratio is -- while Sensus Healthcare, Inc.'s PE ratio is 34.65x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Savara, Inc. is -- versus 2.35x for Sensus Healthcare, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Theriva Biologics, Inc. has a net margin of -- compared to Savara, Inc.'s net margin of --. Savara, Inc.'s return on equity of -78.83% beat Theriva Biologics, Inc.'s return on equity of -171.04%.

Savara, Inc. has a consensus price target of $10.81, signalling upside risk potential of 92.74%. On the other hand Theriva Biologics, Inc. has an analysts' consensus of $7.00 which suggests that it could grow by 3563%. Given that Theriva Biologics, Inc. has higher upside potential than Savara, Inc., analysts believe Theriva Biologics, Inc. is more attractive than Savara, Inc..

Savara, Inc. has a beta of 0.278, which suggesting that the stock is 72.168% less volatile than S&P 500. In comparison Theriva Biologics, Inc. has a beta of 0.343, suggesting its less volatile than the S&P 500 by 65.729%.

Savara, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Savara, Inc. pays -- of its earnings as a dividend. Theriva Biologics, Inc. pays out -- of its earnings as a dividend.

Savara, Inc. quarterly revenues are --, which are smaller than Theriva Biologics, Inc. quarterly revenues of --. Savara, Inc.'s net income of -$29.6M is lower than Theriva Biologics, Inc.'s net income of -$4.4M. Notably, Savara, Inc.'s price-to-earnings ratio is -- while Theriva Biologics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Savara, Inc. is -- versus 0.33x for Theriva Biologics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.